NFE2L2 and Alzheimer disease: The study proved that low-grade chronic neuroinflammation is a “primer” of neurodegeneration, and not just a result, therefore an antioxidant modulator of inflammation as DMF, which targets NRF2, protected from AD disease progression [116].